Eric H. Westin

Medicine · Health Sciences

28h-index4.3kcitations107works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(19), HER2/EGFR in Cancer Research(14), PI3K/AKT/mTOR signaling in cancer(12), Microtubule and mitosis dynamics(11), T-cell and Retrovirus Studies(10)

Publications107 total

Identifying an optimal dose range for clinical development of BT7480 using a fit-for-purpose quantitative system pharmacology (QSP) modeling
2026Open Access
Leveraging digestion-assisted capillary electrophoresis sodium dodecyl sulfate (CE-SDS) to monitor galactosylation in monoclonal antibodies
Journal of Pharmaceutical and Biomedical Analysis·2025
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α<i>‐</i>positive ovarian cancer: Justification of therapeutic dose regimen
British Journal of Clinical Pharmacology·2024· 6 cited
Exposure-Response Relationships of Mirvetuximab Soravtansine in Patients with Folate Receptor-α Positive Ovarian Cancer: Justification of Therapeutic Dose Regimen
2024Open Access
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐<i>α</i> positive ovarian cancer: The antibody–drug conjugate, payload and metabolite
British Journal of Clinical Pharmacology·2023· 11 citedOpen Access
Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Data from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Figures 1-5 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Data from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Supplementary Information from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Information from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Figures 1-5 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Tables 1-2 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Tables 1-2 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
2023Open Access
Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Data from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
2023Open Access
Data from A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Flossie Wong‐Staal(8), I. David Goldman(8), Robert C. Gallo(6), Michael F. Clarke(4), Kevin E. Brigle(4), John D. Schuetz(4), Alessandra Eva(3), Larry H. Matherly(3), Takis S. Papas(2), E. Premkumar Reddy(2), Steven R. Tronick(2), S A Aaronson(2), Michael J. Smith(2), Edward V. Prochownik(2), Michael F. Clarke(2), Steven F. Josephs(2), Lee Ratner(2), Marvin S. Reitz(2), Stephen R. Grant(2), Chirag Patel(2)